Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALN-APOC3 · 1 trial · 1 indication
Part B Only
| Arm | Type | Description |
|---|---|---|
| ALN-APOC3 Ascending Cohorts | EXPERIMENTAL | Part A: Ascending Cohorts Randomized as described in the protocol May include optional cohorts |
| Placebo | PLACEBO_COMPARATOR | Part A and Part B: Randomized as described in the protocol |
| ALN-APOC3 low-dose | EXPERIMENTAL | Part B: Parallel Arm Randomized as described in the protocol |
| ALN-APOC3 medium-dose | EXPERIMENTAL | Part B: Parallel Arm Randomized as described in the protocol |
| ALN-APOC3 high-dose | EXPERIMENTAL | Part B: Parallel Arm Randomized as described in the protocol |
| Name | Type | Description |
|---|---|---|
| ALN-APOC3 | DRUG | Administered as per the protocol |
| Matching Placebo | DRUG | Administered as per the protocol |
Key Inclusion Criteria: 1. Judged by the investigator to be in good health based on medical history, physical examination, vital signs, Electrocardiograms (ECG's) and laboratory safety testing, as defined in the protocol 2. Participants can enter the study under one of the following options, as def...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 2 | PHASE3 | Lepodisiran |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Enlicitide, Rosuvastatin |
| NewAmsterdam Pharma Company N.V. | NAMS | 3 | PHASE3 | obicetrapib, ezetimibe daily |
| AstraZeneca PLC | AZN | 3 | PHASE2 | AZD0780, Rosuvastatin |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE1 | ARO-DIMERPA |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX310 |
| HeartFlow, Inc. | HTFL | 1 | N/A | Rosuvastatin |
ALN-APOC3 is an investigational small molecule being developed for the treatment of dyslipidemia, a condition characterized by abnormal levels of lipids in the blood. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
ALN-APOC3 is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol REGN. The drug is in Phase 1 clinical development for dyslipidemia.
ALN-APOC3 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. One Phase 1 clinical trial has been completed, and the drug is not currently in any active trials.
ALN-APOC3 has been studied in one completed Phase 1 clinical trial, identified as NCT06784349. This trial enrolled 32 adult participants with dyslipidemia in Moldova. The study was randomized, double-blind, and placebo-controlled, and it included healthy volunteers.
No alternative names for ALN-APOC3 have been reported. It is identified solely by its code name ALN-APOC3 and is being developed by Regeneron Pharmaceuticals for dyslipidemia.